About Us
Our Mission & Values
Leadership Team
Board of Directors
Partners
Corporate Giving
Responsibility
Press Releases
Medicines
Science
Clinical Trials
Publications
Treatment Access
Patients & Caregivers
Our Commitment to Patients
Patient Voices
CKD with Hyperphosphatemia
IBS-C
Join Us
Working at Ardelyx
Benefits
Open Positions
Medical Professionals
Investors & Media
About Us
Our Mission & Values
Leadership Team
Board of Directors
Partners
Corporate Giving
Responsibility
Press Releases
Medicines
Science
Clinical Trials
Publications
Treatment Access
Patients & Caregivers
Our Commitment to Patients
Patient Voices
CKD with Hyperphosphatemia
IBS-C
Join Us
Working at Ardelyx
Benefits
Open Positions
Medical Professionals
Investors & Media
Publications
Disease Area
Hyperphosphatemia
IBS-C
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Filter
The Effects of Tenapanor on Serum Fibroblast Growth Factor 23 in Patients Receiving Hemodialysis with Hyperphosphatemia
Nephrology Dialysis Transplantation
Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers
Clinical Drug Investigation
Inhibition of Sodium/Hydrogen Exchanger 3 in the Gastrointestinal Tract by Tenapanor Reduces Paracellular Phosphate Permeability
Science Translational Medicine
An Evaluation of the Pharmacodynamics, Safety, and Tolerability of the Potassium Binder RDX7675
The Journal of Clinical Pharmacology
Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5)
Journal of Medicinal Chemistry
Pages:
1
2
3
4
5
6
7
8
Load More
Sorry, nothing found in this query